Notice Information
Notice Title
NHS National Generic Pharmaceuticals Wave 13
Notice Description
Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 - 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 - 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 - 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 - 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 - 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 - 31 January 2023 (12 months)
Lot Information
Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)
Invitation to offer for NHS National Generic Pharmaceuticals Wave 13
Offer reference number: CM/PHG/17/5532
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement:
Transition (Everolimus)
CESW: 1 March 2022 - 30 September 2023 (19 months)
LSNE: 1 March 2022 - 31 January 2023 (11 months)
NWLN: 1 March 2022 - 31 January 2023 (11 months)
Oral Products plus non-parenterals
All Regions: 1 March 2022 - 31 May 2024 (27 months)
Hospital Only Products
CESW: 1 February 2022 - 30 September 2023 (20 months)
LSNE: 1 February 2022 - 31 May 2024 (28 months)
NWLN: 1 February 2022 - 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Options: Option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.
Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenteralsInvitation to offer for NHS National Generic Pharmaceuticals Wave 13
Offer reference number: CM/PHG/17/5532
Period of framework agreement:The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement:
Transition (Everolimus)
CESW: 1 March 2022 - 30 September 2023 (19 months)
LSNE: 1 March 2022 - 31 January 2023 (11 months)
NWLN: 1 March 2022 - 31 January 2023 (11 months)
Oral Products plus non-parenterals
All Regions: 1 March 2022 - 31 May 2024 (27 months)
Hospital Only Products
CESW: 1 February 2022 - 30 September 2023 (20 months)
LSNE: 1 February 2022 - 31 May 2024 (28 months)
NWLN: 1 February 2022 - 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Options: Option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.
Lot 3 - CM/PHG/17/5532/02 Hospital Only ProductsInvitation to offer for NHS National Generic Pharmaceuticals Wave 13
Offer reference number: CM/PHG/17/5532
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement:
Transition (Everolimus)
CESW: 1 March 2022 - 30 September 2023 (19 months)
LSNE: 1 March 2022 - 31 January 2023 (11 months)
NWLN: 1 March 2022 - 31 January 2023 (11 months)
Oral Products plus non-parenterals
All Regions: 1 March 2022 - 31 May 2024 (27 months)
Hospital Only Products
CESW: 1 February 2022 - 30 September 2023 (20 months)
LSNE: 1 February 2022 - 31 May 2024 (28 months)
NWLN: 1 February 2022 - 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Options: Option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-02be28
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/001128-2022
- Current Stage
- Award
- All Stages
- Tender, Award
Procurement Classification
- Notice Type
- Award Notice
- Procurement Type
- Framework
- Procurement Category
- Goods
- Procurement Method
- Open
- Procurement Method Details
- Open procedure
- Tender Suitability
- Not specified
- Awardee Scale
- Large, SME
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33600000 - Pharmaceutical products
Notice Value(s)
- Tender Value
- £1,637,875,080 £1B-£10B
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- £1
Notice Dates
- Publication Date
- 14 Jan 20224 years ago
- Submission Deadline
- 26 Jul 2021Expired
- Future Notice Date
- Not specified
- Award Date
- Not specified
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Cancelled
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- The NHS Commissioning Board (operating under the name of NHS England)
- Contact Name
- Available with D3 Tenders Premium →
- Contact Email
- Available with D3 Tenders Premium →
- Contact Phone
- Available with D3 Tenders Premium →
Buyer Location
- Locality
- RUNCORN
- Postcode
- WA7 2ES
- Postcode Area
- Warrington
- Country
- England
-
- Major Region (ITL 1)
- TLD North West (England)
- Basic Region (ITL 2)
- TLD7 Merseyside
- Small Region (ITL 3)
- TLD71 East Merseyside
- Delivery Location
- Not specified
-
- Local Authority
- Halton
- Electoral Ward
- Halton Lea
- Westminster Constituency
- Runcorn and Helsby
Supplier Information
- Number of Suppliers
- 131
- Supplier Names
Dr.Reddy's Laboratories (UK) Limited
Mercury Pharmaceuticals Limited
Glenmark Pharmaceuticals Europe Ltd
Organon Pharmaceuticals UK Ltd
Alliance Pharmaceuticals Limited
Alissa Healthcare Research Limited
Merck Sharpe & Dohme (UK) Limited
Waverley Pharma Europe Limited
Recordati Rare Diseases UK Ltd
Norgine Pharmaceuticals Limited
Further Information
Open Contracting Data Standard (OCDS)
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.